Vesta
Approach
Company
Careers
News & Resources
Login
Contact
FEATURED
Development and Validation of Generalizable Interpretable AI Biomarker to Predict Clinical Outcomes in BCG-Treated Patients with Non-Muscle Invasive Bladder Cancer
May 1, 2024
News & Resources
Latest News
Valar Labs debuts AI-powered cancer care prediction tool and secures $22M
TechCrunch
May 2024
Valar Labs debuts AI-powered cancer care prediction tool and secures $22M
TechCrunch
May 2024
Valar Labs Announces $22 Million Series A to Advance Vesta, First AI Diagnostic Test to Predict Treatment Response in Bladder Cancer, and Catalyze Expansion in Other Cancers
Business Wire
May 2024
Valar Labs Announces $22 Million Series A to Advance Vesta, First AI Diagnostic Test to Predict Treatment Response in Bladder Cancer, and Catalyze Expansion in Other Cancers
Business Wire
May 2024
Announcing Our $22 Million Series A to Accelerate AI in Precision Oncology
Blog
May 2024
Announcing Our $22 Million Series A to Accelerate AI in Precision Oncology
Blog
May 2024